This segment focuses on the development of therapies for rare metabolic diseases, with a primary emphasis on Galactosemia and Sorbitol Dehydrogenase Deficiency (SORD). The lead product candidate, AT-007 (Govorestat), is designed to address the underlying metabolic imbalances in these conditions. Research and development activities include preclinical studies, clinical trials (Phase 1/2 and pediatric studies), and regulatory interactions. The therapeutic approach involves targeting validated molecular targets to reduce toxic metabolites and improve patient outcomes. The segment aims to provide innovative treatments for patients with limited or no existing therapeutic options, thereby improving their quality of life and long-term health. Future opportunities include expanding the application of AT-007 to other related metabolic disorders and securing regulatory approvals in key markets.

This segment is dedicated to developing therapies for diabetic complications, including Diabetic Cardiomyopathy (DCM) and Diabetic Peripheral Neuropathy (DPN). The primary focus is on AT-001 (caficrestat), a novel compound in Phase III clinical trials. Research and development efforts involve conducting clinical trials to assess the efficacy and safety of AT-001 in improving cardiac function and reducing neuropathic pain in diabetic patients. The therapeutic strategy targets specific molecular pathways implicated in the pathogenesis of DCM and DPN. The segment aims to address the significant unmet medical needs in diabetic patients by providing treatments that can prevent or delay the progression of these debilitating complications. Future opportunities include exploring the potential of AT-001 in other diabetic complications and expanding the market reach through strategic partnerships and regulatory approvals.